Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study
Open accessAbstract
Immune checkpoint inhibitors, including anti–programmed cell death-1 (PD-1) antibodies, have become promising treatments for a variety of advanced malignancies. However, these medicines can cause immune-related adverse events (irAEs), including endocrinopathies. This study examined the incidence of endocrine irAEs induced by nivolumab. Sixty-six patients treated with nivolumab at Nagoya University Hospital were prospectively evaluated for pituitary hormones, thyroid function, antithyroid antibodies (Abs), and glucose levels every 6 weeks after the initiation of nivolumab for 24 weeks. Four out of 66 patients developed destructive thyroiditis, and three patients developed hypothyroidism requiring levothyroxine replacement. The prevalence of positive anti-thyroglobulin Abs (TgAbs) and/or anti–thyroid peroxidase Abs (TPOAbs) at baseline was significantly higher in the group that developed destructive thyroiditis (3/4) compared with the group that did not develop thyroiditis (3/62; P = 0.002). There were no significant differences in other clinical variables between the groups. There were no endocrine irAEs other than destructive thyroiditis during the 24 weeks. The prevalence of TgAbs and/or TPOAbs at baseline was not associated with the development of other irAEs, including pneumonitis, colitis, or skin reactions. Our real-world data showed that destructive thyroiditis was an endocrine irAE that was frequently induced by nivolumab and was significantly associated with positive TgAbs and/or TPOAbs before treatment. Our findings indicate that evaluating these Abs before treatment may help identify patients with a high risk of thyroidal irAEs and may have important clinical benefit.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Positive TPOAb and/or thyroglobulin autoantibodies (TgAb) are associated with a 40 to 70% risk of hypothyroidism during immune checkpoint inhibitor (ICPi) treatment.
“Two retrospective and two prospective studies reported that positive TPOAb and/or thyroglobulin autoantibodies (TgAb) are associated with a 40 to 70% risk of hypothyroidism during treatment”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [54]
The Results and Discussion (pages unavailable in our copy) report that 3 of 6 antibody-positive patients developed destructive thyroiditis during nivolumab treatment, a 50% incidence. But 50% is the figure for thyroiditis, not hypothyroidism: the Discussion says only three of the four thyroiditis cases progressed to hypothyroidism, and the Results identify one of those cases as antibody-negative. The paper therefore does not support a 40–70% hypothyroidism risk in antibody-positive patients. (LLM, conf=0.87)
Experimental — accuracy not yet measuredPatients who had ICPi-induced hypothyroidism had positive anti-thyroid autoantibodies in 75 to 100% of cases.
“and that patients who had ICPi-induced hypothyroidism had positive anti-thyroid autoantibodies in 75 to 100% of cases [54,55,56,57].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [54]
Male gender and older age may be risk factors for hypophysitis, though this has only been observed in one small series.
“Male gender and older age may be risk factors although this has only been observed in one small series.58”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · see citing works
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101 · see citing works
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,564 · see citing works
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,204 · see citing works
Kang, Y., Boku, N., Satoh, T., Ryu, M., Chao, Y., Kato, K., Chung, H. C., Chen, J., Muro, K., Kang, W. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31827-5 · Cited by 2,254 · see citing works
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222 · see citing works
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,342 · see citing works
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2005 · Cited by 1,215 · see citing works
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,090 · see citing works
Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1136 · Cited by 863 · see citing works
Osorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw640 · Cited by 659 · see citing works
Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
Hughes, J. W., Vudattu, N. K., Sznol, M., Gettinger, S. N., Kluger, H. M., Lupsa, B. C., & Herold, K. C. (2015) · Diabetes Care · doi:10.2337/dc14-2349 · Cited by 347 · see citing works
Sznol, M., Postow, M. A., Davies, M. J., Pavlick, A. C., Plimack, E. R., Shaheen, M. F., Veloski, C., & Robert, C. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.002 · Cited by 290 · see citing works
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
González-Rodríguez, E., Rodríguez‐Abreu, D., & on behalf of the Spanish Group for Cancer Immuno-Biotherapy (GETICA) (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0509 · Cited by 251 · see citing works
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
de Filette, J., Jansen, Y., Schreuer, M., Everaert, H., Velkeniers, B., Neyns, B., & Bravenboer, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2300 · Cited by 244 · see citing works
Morganstein, D. L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., & Larkin, J. (2017) · Clinical Endocrinology · doi:10.1111/cen.13297 · Cited by 190 · see citing works
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
Yamauchi, I., Sakane, Y., Fukuda, Y., Fujii, T., Taura, D., Hirata, M., Hirota, K., Ueda, Y., Kanai, Y., Yamashita, Y., et al. (2017) · Thyroid · doi:10.1089/thy.2016.0562 · Cited by 169 · see citing works
Genetic and epigenetic mechanisms in thyroid autoimmunity
Hasham, A., & Tomer, Y. (2012) · Immunologic Research · doi:10.1007/s12026-012-8302-x · Cited by 144 · see citing works
Hyponatraemia secondary to nivolumab-induced primary adrenal failure
Trainer, H., Hulse, P., Higham, C. E., Trainer, P., & Lorigan, P. (2016) · Endocrinology, Diabetes & Metabolism Case Reports · doi:10.1530/edm-16-0108 · Cited by 117 · see citing works
Ehlers, M., Thiel, A., Bernecker, C., Porwol, D., Papewalis, C., Willenberg, H. S., Schinner, S., Hautzel, H., Scherbaum, W. A., & Schott, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2178 · Cited by 79 · see citing works
Nivolumab: A Review in Advanced Melanoma
Scott, L. J. (2015) · Drugs · doi:10.1007/s40265-015-0442-6 · Cited by 57 · see citing works
Nivolumab-induced thyroid dysfunction
Tanaka, R., Fujisawa, Y., Maruyama, H., Nakamura, Y., Yoshino, K., Ohtsuka, M., & Fujimoto, M. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw036 · Cited by 47 · see citing works
Pani, F., Atzori, F., Baghino, G., Boi, F., Tanca, L., Ionta, M. T., & Mariotti, S. (2015) · Thyroid · doi:10.1089/thy.2015.0170 · Cited by 45 · see citing works
Shang, Y. H., Zhang, Y., Li, J., Li, P., & Zhang, X. (2017) · Immunotherapy · doi:10.2217/imt-2016-0147 · Cited by 39 · see citing works
Case of hypophysitis caused by nivolumab
Ishikawa, M., & Oashi, K. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13437 · Cited by 38 · see citing works
Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma
Tsiogka, A., Jansky, G. L., Bauer, J. W., & Koelblinger, P. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000384 · Cited by 37 · see citing works
Nivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung
Verma, I., Modi, A., Tripathi, H., & Agrawal, A. (2016) · BMJ Case Reports · doi:10.1136/bcr-2015-213692 · Cited by 18 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Immune-related adverse events of checkpoint inhibitors
Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,447 · see citing works
Endocrine toxicities of immune checkpoint inhibitors
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441 · see citing works
de Filette, J., Andreescu, C., Cools, F., Bravenboer, B., & Velkeniers, B. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0843-3366 · Cited by 381 · see citing works
Rheumatic immune-related adverse events from cancer immunotherapy
Calabrese, L. H., Calabrese, C. M., & Cappelli, L. C. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0074-9 · Cited by 233 · see citing works
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
Tison, A., Garaud, S., Chiche, L., Cornec, D., & Kostine, M. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00841-0 · Cited by 201 · see citing works
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
de Moel, E. C., Rozeman, E. A., Kapiteijn, E. H., Verdegaal, E. M. E., Grummels, A., Bakker, J. A., Huizinga, T. W. J., Haanen, J. B., Toes, R. E. M., & van der Woude, D. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0245 · Cited by 191 · see citing works
PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients
Kotwal, A., Kottschade, L. A., & Ryder, M. M. (2019) · Thyroid · doi:10.1089/thy.2019.0250 · Cited by 168 · see citing works
Kimbara, S., Fujiwara, Y., Iwama, S., Ohashi, K., Kuchiba, A., Arima, H., Yamazaki, N., Kitano, S., Yamamoto, N., & Ohe, Y. (2018) · Cancer Science · doi:10.1111/cas.13800 · Cited by 158 · see citing works
Self-citationYamauchi, I., Yasoda, A., Matsumoto, S., Sakamori, Y., Kim, Y. H., Nomura, M., Otsuka, A., Yamasaki, T., Saito, R., Kitamura, M., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216954 · Cited by 137 · see citing works
Kobayashi, T., Iwama, S., Yasuda, Y., Okada, N., Okuji, T., Ito, M., Onoue, T., Goto, M., Sugiyama, M., Tsunekawa, T., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000779 · Cited by 132 · see citing works
Self-citationStelmachowska‐Banaś, M., & Czajka-Oraniec, I. (2020) · Endocrine Connections · doi:10.1530/ec-20-0342 · Cited by 139 · see citing works
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 130 · see citing works
Autoimmune complications of immunotherapy: pathophysiology and management
Chan, K. K., & Bass, A. R. (2020) · BMJ · doi:10.1136/bmj.m736 · Cited by 125 · see citing works
Arima, H., Iwama, S., Inaba, H., Ariyasu, H., Makita, N., Otsuki, M., Kageyama, K., Imagawa, A., & Akamizu, T. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0163 · Cited by 108 · see citing works
Self-citationPredictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
Les, I., Martínez, M., Pérez-Francisco, I., Cabero, M., Teijeira, L., Arrazubi, V., Torrego, N., Campillo-Calatayud, A., Elejalde, I., Kochan, G., et al. (2023) · Cancers · doi:10.3390/cancers15051629 · Cited by 100 · see citing works
Kotwal, A., Gustafson, M. P., Bornschlegl, S., Kottschade, L. A., Delivanis, D. A., Dietz, A. B., Gandhi, M. J., & Ryder, M. M. (2020) · Thyroid · doi:10.1089/thy.2020.0075 · Cited by 96 · see citing works
Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury
Zhang, Z., Zhou, J., Verma, V., Liu, X., Wu, M., Yu, J., & Chen, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.774807 · Cited by 95 · see citing works
Basak, E. A., van der Meer, J. W. M., Hurkmans, D. P., Schreurs, M. W. J., Hoop, E. O., van der Veldt, A. A. M., Bins, S., Joosse, A., Koolen, S. L. W., Debets, R., et al. (2020) · Thyroid · doi:10.1089/thy.2019.0726 · Cited by 92 · see citing works
Álvarez‐Sierra, D., Marín, A., Ruiz-Blázquez, P., de Jesús‐Gil, C., Iglesias, C., González, Ó., Casteràs, A., Ferrer, R., Nuciforo, P. G., Colobrán, R., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.05.013 · Cited by 89 · see citing works
Yasuda, Y., Iwama, S., Sugiyama, D., Okuji, T., Kobayashi, T., Ito, M., Okada, N., Enomoto, A., Ito, S., Yan, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb7495 · Cited by 87 · see citing works
Self-citationIbis, B., Aliazis, K., Cao, C., Yenyuwadee, S., & Boussiotis, V. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1197364 · Cited by 89 · see citing works
First line Immunotherapy for Non-Small Cell Lung Cancer
Nasser, N. J., Gorenberg, M., & Agbarya, A. (2020) · Pharmaceuticals · doi:10.3390/ph13110373 · Cited by 82 · see citing works
Kobayashi, T., Iwama, S., Sugiyama, D., Yasuda, Y., Okuji, T., Ito, M., Ito, S., Sugiyama, M., Onoue, T., Takagi, H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002493 · Cited by 83 · see citing works
Self-citationThyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer
Muir, C. A., Menzies, A. M., Clifton-Bligh, R. J., & Tsang, V. (2020) · Thyroid · doi:10.1089/thy.2020.0032 · Cited by 81 · see citing works
Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
Xu, Y., Fu, Y., Zhu, B., Wang, J., & Zhang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02023 · Cited by 81 · see citing works
Okada, N., Iwama, S., Okuji, T., Kobayashi, T., Yasuda, Y., Wada, E., Onoue, T., Goto, M., Sugiyama, M., Tsunekawa, T., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0736-7 · Cited by 78 · see citing works
Self-citationImmune checkpoint inhibitor-related thyroid dysfunction
Iwama, S., Kobayashi, T., Yasuda, Y., & Arima, H. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101660 · Cited by 76 · see citing works
Self-citationDwivedi, S. N., Kalaria, T., & Buch, H. (2022) · Journal of Clinical Pathology · doi:10.1136/jcp-2022-208290 · Cited by 79 · see citing works
Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders
Jannin, A., Penel, N., Ladsous, M., Vantyghem, M., & Cao, C. D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.015 · Cited by 75 · see citing works
Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies
Sakakida, T., Ishikawa, T., Chihara, Y., Harita, S., Uchino, J., Tabuchi, Y., Komori, S., Asai, J., Narukawa, T., Arai, A., et al. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02214-8 · Cited by 74 · see citing works
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies
Willsmore, Z. N., Harris, R. J. C., Crescioli, S., Hussein, K., Kakkassery, H., Thapa, D., Cheung, A., Chauhan, J., Bax, H. J., Chenoweth, A. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.622442 · Cited by 72 · see citing works
Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes
Peiró, I., Palmero, R., Iglesias, P., Díez, J. J., Simó-Servat, A., Marín‐Jiménez, J. A., Jiménez, L., Domingo‐Doménech, E., Mancho-Fora, N., Nadal, E., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01871-7 · Cited by 63 · see citing works
Thyroid-related adverse events induced by immune checkpoint inhibitors
Chera, A., Stancu, A. L., & Bucur, O. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1010279 · Cited by 61 · see citing works
Baseline TSH Level is Associated with Risk of Anti–PD-1–Induced Thyroid Dysfunction
Pollack, R. M., Kagan, M., Lotem, M., & Dresner–Pollak, R. (2019) · Endocrine Practice · doi:10.4158/ep-2018-0472 · Cited by 59 · see citing works
Zhan, L., Feng, H.-F., Liu, H., Guo, L., Chen, C., Yao, X.-L., & Sun, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.649863 · Cited by 60 · see citing works
Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
Rahman, M. M., Behl, T., Islam, M. R., Islam, M. R., Islam, M. R., Albarrati, A., Albratty, M., Meraya, A. M., & BUNGAU, S. G. (2022) · Molecules · doi:10.3390/molecules27123798 · Cited by 54 · see citing works
Wang, M., Liang, H., Wang, W., Zhao, S., Cai, X., Zhao, Y., Li, C., Cheng, B., Xiong, S., Li, J., et al. (2020) · Cancer · doi:10.1002/cncr.33270 · Cited by 52 · see citing works
Endocrine side effects of immune checkpoint inhibitors
Cardona, Z., Sosman, J. A., Chandra, S., & Huang, W. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1157805 · Cited by 55 · see citing works
Mazarico, I., Capel, I., Giménez‐Palop, O., Albert, L., Berges, I., Luchtenberg, F., García, Y. G., Fernandez-Morales, L. A., de Pedro, V. J., Caixàs, A., et al. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01058-x · Cited by 51 · see citing works
Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors
Quandt, Z., Young, A., Perdigoto, A. L., Herold, K. C., & Anderson, M. S. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-050219-034237 · Cited by 51 · see citing works
Sakakida, T., Ishikawa, T., Uchino, J., Chihara, Y., Komori, S., Asai, J., Narukawa, T., Arai, A., Kobayashi, T., Tsunezuka, H., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10466 · Cited by 50 · see citing works
Self-citationImmune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index
Pollack, R. M., Ashash, A., Cahn, A., Rottenberg, Y., Stern, H., & Dresner–Pollak, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa458 · Cited by 49 · see citing works
Immunotherapy-induced endocrinopathies: assessment, management and monitoring
Nogueira, E. F., Newsom‐Davis, T., & Morganstein, D. L. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819896182 · Cited by 48 · see citing works
Brilli, L., Danielli, R., Campanile, M., Secchi, C., Ciuoli, C., Calabrò, L., Pilli, T., Cartocci, A., Pacini, F., Giacomo, A. M. D., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01480-6 · Cited by 48 · see citing works
Yoon, J. H., Hong, A. R., Kim, H. K., & Kang, H. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.906 · Cited by 46 · see citing works
König, D., & Laubli, H. P. (2020) · Pharmacology · doi:10.1159/000509081 · Cited by 48 · see citing works
Bai, R., Chen, N., Chen, X., Li, L., Song, W., Li, W., Zhao, Y., Zhang, Y., Han, F., Lyu, Z., et al. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0052 · Cited by 46 · see citing works
Iwama, S., Kobayashi, T., & Arima, H. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01077-6 · Cited by 46 · see citing works
Self-citationImmune-Related Adverse Events: A Case-Based Approach
Connolly, C. M., Bambhania, K., & Naidoo, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00530 · Cited by 45 · see citing works
Yuen, K. C. J., Samson, S. L., Bancos, I., Gosmanov, A. R., Jasim, S., Fecher, L. A., & Weber, J. S. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.04.010 · Cited by 45 · see citing works
Iwama, S., Kobayashi, T., Yasuda, Y., Okuji, T., Ito, M., Ando, M., Zhou, X., Yamagami, A., Onoue, T., Kawaguchi, Y., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab829 · Cited by 44 · see citing works
Self-citationRationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Tai, D. W.-M., Choo, S. P., & Chew, V. (2019) · Cancers · doi:10.3390/cancers11121926 · Cited by 43 · see citing works
Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
Les, Í., Kareaga, M. M., Narro, A., Pérez, I., Sánchez, C., Puntí, L., Anaut, P., Eguiluz, S., Herrera, A., & Domínguez, S. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1931956 · Cited by 42 · see citing works
Daban, A., Gonnin, C., Phan, L., Saldmann, A., Granier, C., Louët, A. L., Beller, C. L., Pouchot, J., Weiss, L., Tartour, É., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2204754 · Cited by 42 · see citing works
Lopez-Olivo, M. A., Kachira, J. J., Abdel‐Wahab, N., Pundole, X., Aldrich, J. D., Carey, P., Khan, M. A., Geng, Y., Pratt, G. F., & Suarez-Almazor, M. E. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114148 · Cited by 41 · see citing works
Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
Olsen, T. A., Zhuang, T., Caulfield, S. E., Martini, D. J., Brown, J. T., Carthon, B. C., Küçük, Ö., Harris, W. B., Bilen, M. A., & Nazha, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.779915 · Cited by 41 · see citing works
Chieng, J. H. L., Htet, Z. W., Zhao, J. J., Tai, E. S., Tay, S. H., Huang, Y., Wong, A. S. C., & Yang, S. P. (2022) · Cancers · doi:10.3390/cancers14112687 · Cited by 40 · see citing works
Iwama, S., Kobayashi, T., & Arima, H. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1007 · Cited by 38 · see citing works
Self-citationYang, J., He, X., Lv, Q., Jing, J., & Shi, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00726 · Cited by 36 · see citing works
Ito, T., Ishigami, M., Yamamoto, T., Mizuno, K., Yamamoto, K., Imai, N., Ishizu, Y., Honda, T., Kawashima, H., Yasuda, S., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10238-y · Cited by 36 · see citing works
Self-citationZhou, X., Iwama, S., Kobayashi, T., Ando, M., & Arima, H. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad231 · Cited by 35 · see citing works
Self-citationReal-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08)
Takahashi, Y., Sunakawa, Y., Inoue, E., Kawabata, R., Ishiguro, A., Kito, Y., Akamaru, Y., Takahashi, M., Yabusaki, H., Matsuyama, J., et al. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01237-x · Cited by 35 · see citing works
Sbardella, E., Tenuta, M., Sirgiovanni, G., Gianfrilli, D., Pozza, C., Venneri, M. A., Cortesi, E., Marchetti, P., Lenzi, A., Gelibter, A. J., et al. (2019) · Clinical Endocrinology · doi:10.1111/cen.14135 · Cited by 34 · see citing works
Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
Peiffert, M., Cugnet-Anceau, C., Dalle, S., Chikh, K., Assaad, S., Disse, E., Raverot, G., Borson-Chazot, F., & Abeillon-du Payrat, J. (2021) · Cancers · doi:10.3390/cancers13081944 · Cited by 33 · see citing works
López-Guerra, N., Matas-García, A., Serra‐García, L., Morgado‐Carrasco, D., Padrosa, J., Aldecoa, I., Duque-Jaimez, Y., Casal-Domínguez, M., Muñoz-Braceras, S., Aránega, R., et al. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103375 · Cited by 33 · see citing works
Wu, L., Xu, Y., Wang, X., Cheng, X., Zhang, Y., Wang, Y., Fan, X., Zhao, H., Liu, H., Chai, X., et al. (2023) · Endocrine · doi:10.1007/s12020-023-03323-9 · Cited by 33 · see citing works
Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
Yamauchi, I., & Yabe, D. (2025) · European Thyroid Journal · doi:10.1530/etj-24-0328 · Cited by 34 · see citing works
Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review
Okura, N., Asano, M., Uchino, J., Morimoto, Y., Iwasaku, M., Kaneko, Y., Yamada, T., Fukui, M., & Takayama, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072033 · Cited by 31 · see citing works
Barth, D. A., Stanzer, S., Terzic, J. A., Bauernhofer, T., Absenger, G., Posch, F., Lipp, R., Halm, M., Szkandera, J., Balić, M., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4675 · Cited by 29 · see citing works
Anti-pituitary antibodies as a marker of autoimmunity in pituitary glands
Iwama, S., & Arima, H. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0436 · Cited by 29 · see citing works
Self-citationQuandt, Z., Kim, S. J., Villanueva-Meyer, J. E., Coupe, C., Young, A., Kang, J. H., Yazdany, J., Schmajuk, G., Rush, S., Ziv, E., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad012 · Cited by 28 · see citing works
Shalit, A., Sarantis, P., Koustas, E., Trifylli, E.-M., Matthaios, D., & Karamouzis, M. V. (2023) · Cancers · doi:10.3390/cancers15020375 · Cited by 29 · see citing works
Bardoscia, L., Pasinetti, N., Triggiani, L., Cozzi, S., & Sardaro, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.746853 · Cited by 27 · see citing works
Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient
Shibaki, R., Murakami, S., Oki, K., & Ohe, Y. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz087 · Cited by 25 · see citing works
Koyama, J., Horiike, A., Yoshizawa, T., Dotsu, Y., Ariyasu, R., Saiki, M., Sonoda, T., Uchibori, K., Nishikawa, S., Kitazono, S., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.04.102 · Cited by 23 · see citing works
Inaba, H., Ariyasu, H., Takeshima, K., Iwakura, H., & Akamizu, T. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0234 · Cited by 23 · see citing works
Deligiorgi, M. V., Sagredou, S., Vakkas, L., & Trafalis, D. T. (2021) · Cancers · doi:10.3390/cancers13215277 · Cited by 22 · see citing works
Kobayashi, T., Iwama, S., Yamagami, A., Yasuda, Y., Okuji, T., Ito, M., Zhou, X., Ando, M., Onoue, T., Miyata, T., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac467 · Cited by 22 · see citing works
Self-citationClinical burden of immune checkpoint inhibitor-induced pneumonitis
Sakamoto, K., Fukihara, J., Morise, M., & Hashimoto, N. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.05.008 · Cited by 21 · see citing works
Self-citationYamauchi, I., Taura, D., Hakata, T., Fujita, H., Okamoto, K., Ueda, Y., Fujii, T., & Inagaki, N. (2020) · Clinical Endocrinology · doi:10.1111/cen.14349 · Cited by 21 · see citing works
Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors
Shibata, Y., Murakami, S., & Kato, T. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1898584 · Cited by 21 · see citing works
Izawa, N., Shiokawa, H., Onuki, R., Hamaji, K., Morikawa, K., Saji, H., Ohashi, H., Kasugai, S., Hayakawa, N., Ohara, T., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100415 · Cited by 20 · see citing works
Les, Í., Pérez-Francisco, I., Cabero, M., Sánchez, C., Hidalgo, M., Teijeira, L., Arrazubi, V., Domínguez, S., Anaut, P., Eguiluz, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.894550 · Cited by 19 · see citing works
Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders
Aoun, R., Gratch, D., Kaminetzky, D., & Kister, I. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01306-x · Cited by 20 · see citing works
Endocrinopathies Associated With Immune Checkpoint Inhibitor Use
Kotwal, A., Kennedy, R., Kikani, N. J., Thosani, S., Goldner, W. S., & Shariff, A. I. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.03.023 · Cited by 20 · see citing works
Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
Dudzińska, M., Szczyrek, M., Wojas‐Krawczyk, K., Świrska, J., Chmielewska, I., & Zwolak, A. (2020) · Cancers · doi:10.3390/cancers12082314 · Cited by 18 · see citing works
Sanchez, K. G., Page, D. B., & Urba, W. J. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.009 · Cited by 18 · see citing works
George, A. S., Fernandez, C. J., Eapen, D., & Pappachan, J. M. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.1.21 · Cited by 18 · see citing works
Chye, A., Allen, I., Barnet, M. B., & Burnett, D. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894015 · Cited by 17 · see citing works
Horinouchi, H., Nishio, M., Hida, T., Nakagawa, K., Sakai, H., Nogami, N., Atagi, S., Takahashi, T., Saka, H., Takenoyama, M., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2411 · Cited by 15 · see citing works
Lui, D. T. W., Lee, C., Tang, V., Fong, C. H. Y., Lee, A. C. H., Chiu, J. W. Y., Leung, R. C. Y., Kwok, G. W., Li, B. C. W., Cheung, T. T., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.01.017 · Cited by 14 · see citing works
Ishi, A., Tanaka, I., Iwama, S., Sakakibara, T., Mastui, T., Kobayashi, T., Hase, T., Morise, M., Sato, M., Arima, H., et al. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej20-0769 · Cited by 14 · see citing works
Self-citationEndocrine immune-related adverse effects of immune-checkpoint inhibitors
Trevisani, V., Iughetti, L., Lucaccioni, L., & Predieri, B. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2256841 · Cited by 15 · see citing works
Percik, R., Liel, Y., Urban, D., Bar, J., Ben‐Ami, E., & Tailakh, M. A. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1958006 · Cited by 13 · see citing works
Endocrine Adverse Events Related with Immune Checkpoint Inhibitors: An Update for Clinicians
Deligiorgi, M. V., Panayiotidis, M. I., & Trafalis, D. T. (2020) · Immunotherapy · doi:10.2217/imt-2019-0132 · Cited by 13 · see citing works
Non-bacterial cystitis caused by pembrolizumab therapy for adenocarcinoma of the lung: a case report
Di, C., Yu, T., & Ni, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1423123 · Cited by 12 · see citing works
Lee, H. J., Manavalan, A. D., Stefan–Lifshitz, M., Schechter, C. B., Maity, A., & Tomer, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1169173 · Cited by 12 · see citing works
Genta, S., Lajkosz, K., Yee, N., Spiliopoulou, P., Heirali, A., Hansen, A. R., Siu, L. L., Saibil, S. D., Stayner, L.-A., Yanekina, M., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02851-6 · Cited by 12 · see citing works
Masaki, K., Miyazaki, M., Kakimoto, H., Fukiage, Y., Fukue, H., Nakashima, A., & Imakyure, O. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247564 · Cited by 12 · see citing works
Yang, Y., Wu, Q., Chen, L., Qian, K., & Xu, X. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-1284 · Cited by 12 · see citing works
- Authors
- Kobayashi, T., Iwama, S., Yasuda, Y., Okada, N., Tsunekawa, T., Onoue, T., Takagi, H., Hagiwara, D., Ito, Y., Morishita, Y., Goto, M., Suga, H., Banno, R., Yokota, K., Hase, T., Morise, M., Hashimoto, N., Ando, M., Kiyoi, H., Gotoh, M., Ando, Y., Akiyama, M., Hasegawa, Y., & Arima, H.
- Affiliations
- Nagoya University (JP)
- Research Center of Health, Physical Fitness and Sports, Nagoya University (JP)
- Nagoya University Hospital (JP)
- Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan
- Corresponding author
- Iwama, Shintaro
- ORCID
- Kobayashi, Tomoko
- Iwama, Shintaro
- Tsunekawa, Taku
- Onoue, Takeshi
- Takagi, Hiroshi
- Hagiwara, Daisuke
- Ito, Yoshihiro
- Morishita, Yoshiaki
- Goto, Motomitsu
- Suga, Hidetaka
- Banno, Ryoichi
- Yokota, Kenji
- Hase, Tetsunari
- Morise, Masahiro
- Hashimoto, Naozumi
- Ando, Masahiko
- Kiyoi, Hitoshi
- Gotoh, Momokazu
- Akiyama, Masashi
- Hasegawa, Yoshinori
- Arima, Hiroshi
- Venue
- Journal of the Endocrine Society
- Publisher
- The Endocrine Society
- Published
- 2018-02-06
- Volume
- 2
- Issue
- 3
- Pages
- 241-251
- ISSN
- 2472-1972 (ISSN-L)
- PMC
- PMC5836529
- OpenAlex
- W2794031826
- Cited by
- 203
- References
- 32
- Citations by year
- 2026: 7 · 2025: 20 · 2024: 29 · 2023: 24 · 2022: 32 · 2021: 26 · 2020: 34 · 2019: 25 · 2018: 5
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Journal of the Endocrine Society (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Nagoya University Repository (NAGOYA Repository) (submittedVersion, other-oa)
- Funders
- Japan Society for the Promotion of Science (17K09921, 16K19552)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- nivolumab, immune checkpoint inhibitors, immune-related adverse events, destructive thyroiditis, thyroid autoantibodies, thyroglobulin antibodies, thyroid peroxidase antibodies, hypothyroidism, PD-1 inhibitors, endocrine adverse events
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
